Gonzalez-Porras et al developed a risk score for evaluating patients with the myelodysplastic syndrome (MDS). The authors are from the Spanish Myelodysplastic Syndrome Registry.
Patient selection: myelodysplasia
Parameters:
(1) karyotype risk from IPSS
(2) percent blasts in the bone marrow
(3) platelet count
(4) age in years
(5) hemoglobin
(6) neutrophil count
|
Parameter |
Finding |
Points |
|
karyotype risk |
intermediate or good |
0 |
|
|
poor |
1 |
|
percent blasts |
<= 5% |
0 |
|
|
> 5% |
1 |
|
platelet count |
>= 30,000 per µL |
0 |
|
|
< 30,000 per µL |
1.5 |
|
age |
<= 70 years of age |
0 |
|
|
> 70 years of age |
1 |
|
hemoglobin |
>= 8 g/dL |
0 |
|
|
< 8 g/dL |
1 |
|
neutrophil count |
>= 500 per µL |
0 |
|
|
< 500 per µL |
1 |
where:
• Poor risk karyotypes: chromosome 7 anomalies, >= 3 abnormalities (complex)
• A neutrophil count < 500 per µL would be severe absolute neutropenia.
score =
= SUM(points for all 6 parameters)
Interpretation:
• minimum score: 0
• maximum score 6.5
• The higher the score the worse the prognosis.
|
Score |
Median Survival (Months) |
|
0 or 1 |
89 |
|
1.5 to 2.5 |
32 |
|
3 to 4 |
12 |
|
4.5 to 6.5 |
8 |
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
